Loading
ZBTB16 (Zinc finger and BTB domain-containing protein 16) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Oesophageal cancer, Skin cancer and 4 more.
Acts as a transcriptional repressor. Transcriptional repression may be mediated through recruitment of histone deacetylases to target promoters. May play a role in myeloid maturation and in the development and/or maintenance of other differentiated tissues.
Open Targets scores its association with cancer at 0.72 (direct and indirect evidence; datatypes affected pathway 0.61, literature 0.98, genetic association 0.43, somatic mutation 0.84, animal model 0.64). IntOGen calls it a driver in 2 cohorts (1 activating, 1 loss-of-function), covering Oesophageal Squamous Cell Carcinoma, Prostate Adenocarcinoma.
In plain words · ZBTB16 (Zinc finger and BTB domain-containing protein 16) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Oesophageal cancer, Skin cancer and 4 more.
ZBTB16 (Zinc finger and BTB domain-containing protein 16) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Oesophageal cancer, Skin cancer and 4 more.
Acts as a transcriptional repressor. Transcriptional repression may be mediated through recruitment of histone deacetylases to target promoters.
No product in this corpus aims at ZBTB16 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
First described 1993. Earliest sequence paper UniProt cites for the protein: Chen et al, EMBO J, 1993, "Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia". Source.
Sources: HGNC HGNC:12930 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q05516 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000109906 (association with cancer (MONDO_0004992) 0.72; per-cancer scores at or above 0.5: prostate cancer 0.51, melanoma 0.52, skin cancer 0.55, breast cancer 0.53, lung cancer 0.52 (GraphQL API, CC0)); IntOGen ZBTB16 (driver in 2 cohorts (Act 1, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Acts as a transcriptional repressor. Transcriptional repression may be mediated through recruitment of histone deacetylases to target promoters. May play a role in myeloid maturation and in the development and/or maintenance of other differentiated tissues. Probable substrate-recognition component of an E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Location: Nucleus; Nucleus, nuclear body (UniProt). Locus 11q23.2 (HGNC).
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Prostate cancer | 1-9% | Deletion or truncating mutation | cBioPortal ZBTB16 deep deletion: 43 of 1,013, 4.2%, in prad_p1000; 17 of 489, 3.5%, in prad_tcga_pan_can_atlas_2018; 13 of 444, 2.9%, in prad_su2c_2019; 8 of 150, 5.3%, in prad_su2c_2015. ZFHX3 mutation: 142 of 2,260, 6.3%, in prostate_msk_2024; 22 of 444, 5.0%, in prad_su2c_2019, with deep deletion 29 of 489, 5.9%, in prad_tcga_pan_can_atlas_2018. | cBioPortal (TCGA) |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
It separates two explanations that are usually run together. Some of the difference in prostate cancer outcomes by race is in the tumour genome and persists when access to the same centre is held constant, and some of it tracks with income rather than with ancestry, so equalising access alone would not eliminate the gap.
The genomic definition of advanced prostate cancer, and the evidence that made molecular testing standard in it. The 19.3 percent DNA repair figure is the direct ancestor of PROfound, TRITON3, PROpel and TALAPRO-2, and the 8 percent germline figure is why a tumour result in this disease has implications for a man's relatives.
Query for this target: (TITLE:"ZBTB16" OR ABSTRACT:"ZBTB16" OR TITLE:"zinc finger and BTB domain containing 16" OR ABSTRACT:"zinc finger and BTB domain containing 16" OR TITLE:"Zinc finger and BTB domain-containing protein 16" OR ABSTRACT:"Zinc finger and BTB domain-containing protein 16" OR TITLE:"ZNF145" OR ABSTRACT:"ZNF145") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ZBTB16, not a curated reading list.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, IntOGen, Lung cancer (all types).
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, IntOGen, Breast cancer (all types).
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, IntOGen, Open Targets Platform.
Shares Differences in prostate cancer genomes by self-reported race, IntOGen, Breast cancer (all types), Open Targets Platform.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, IntOGen.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer.